DocMorris AG (OTCMKTS:ZRSEF – Get Free Report) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 643,190 shares, a growth of 724.0% from the June 30th total of 78,057 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on ZRSEF shares. UBS Group raised DocMorris from a “sell” rating to a “neutral” rating in a research report on Monday, July 20th. Deutsche Bank Aktiengesellschaft raised DocMorris from a “hold” rating to a “buy” rating in a research report on Monday, July 13th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on ZRSEF
DocMorris Price Performance
About DocMorris
DocMorris is a leading European online pharmacy brand and a subsidiary of the Swiss-based Zur Rose Group (OTCMKTS:ZRSEF). Through its digital platform, the company offers mail-order dispensing of prescription medications and over-the-counter health products directly to consumers’ homes.
The company’s core services include the online sale and delivery of prescription and non-prescription drugs, health supplements, personal care items and medical devices. Leveraging its e-commerce infrastructure and proprietary pharmacy management systems, DocMorris also provides digital health solutions such as telemedicine consultations, medication management tools and mobile app-based healthcare services.
Originally launched in the early 2000s in Germany, DocMorris has expanded its reach to serve customers in multiple European countries, including the Netherlands, Belgium, Luxembourg and Switzerland.
Featured Stories
- Five stocks we like better than DocMorris
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for DocMorris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocMorris and related companies with MarketBeat.com's FREE daily email newsletter.
